# US 2026/0008762 A1 · Cannabinoid acids crystalline forms, methods of producing, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0008762 A1
- Document ID: US20260008762A1
- Status: Published application
- Kind: A1
- Application number: 18/867,051
- Filed: 2023-05-22
- Published: 2026-01-08
- Earliest claimed: 2022-05-20
- Applicants: Arizona Board of Regents On Behalf of Arizona State University; Vext Science, Inc.; Bioscitech LLC
- Inventors: Jeffery L. YARGER; Stephen DAVIDOWSKI; Michael SETH
- Web page: https://patentgrep.com/patent/US20260008762A1

## CPC

- C07C 65/19: having unsaturation outside the aromatic ring
- C07D 311/80: Dibenzopyrans; Hydrogenated dibenzopyrans
- C07D 311/78: Ring systems having three or more relevant rings
- C07B 2200/07: Optical isomers
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

This invention is directed to crystalline forms of cannabinoid acids, producing crystalline forms, and methods of use thereof.

## Claims

### Claim at position 1

-17. (canceled)

### Claim 18

A crystalline form of tetrahydrocannabinolic acid (THCa) of the following structure:

### Claim 19 (depends on 18)

The crystalline form of claim 18, wherein the crystalline form is selected from a single component crystalline form or a multicomponent crystalline form.

### Claim 20 (depends on 19)

The crystalline form of claim 19, wherein the multicomponent crystalline form comprises a co-crystal, a salt, or a combination thereof.

### Claim 21 (depends on 19)

The crystalline form of claim 19, wherein the single component crystalline form comprises at least one of the following features (i) to (ix):
(i) a powder x-ray diffraction (PXRD) pattern comprising at least one characteristic peak at 2θ angles of about 6.5, 8.8, 9.6, 10.1, 12.7, 13.1, 14.1, 15.1, 16.4, 17.0, 18.7, 19.4, 19.8, 20.3, 21.3, 21.7, 22.7, 23.6, 25.3, 27.1, and 29.4;
(ii) a single crystal x-ray diffraction (SCXRD) pattern comprising at least one characteristic peak at 2θ angles described herein;
(iii) a Fourier transform infrared spectroscopy spectrum comprising at least one characteristic peak at about 742, 820, 887, 973, 1029, 1070, 1107, 1167, 1234, 1360, 1428, 1547, 1644, 1700, 2860, 2926, 2957 cm−1;
(iv) a liquid state 1H nuclear magnetic resonance (NMR) spectrum comprising at least one characteristic peak at about 0.903, 1.11, 1.35(m), 1.44, 1.58(m), 1.68, 1.92(m), 2.17, 2.79(m), 2.95(m), 3.23, 6.26, 6.39, 11.70, 12.16 ppm in CDCl3;
(v) a liquid state 13C (1H decoupled) nuclear magnetic resonance (NMR) spectrum comprising at least one characteristic peak at about 14.1, 19.5, 22.5, 23.4, 25.0, 27.4, 31.2, 31.3, 32.0, 33.5, 36.5, 45.6, 78.9, 102.3, 109.9, 112.7, 123.6, 133.9, 147.0, 159.8, 164.7, 176.5 ppm in CDCl3;
(vi) a solid state 1H NMR spectrum comprising at least one characteristic peak at about 1.5, 6.2, 11.2, 11.8, 12.7 ppm;
(vii) a solid state 1H-13C cross polarization (CP) magic angle spinning (MAS) NMR spectrum comprising at least one characteristic peak at about 13.8, 15.4, 17.9, 19.3, 20.7, 23.6, 24.2, 24.6, 25.1, 25.9, 26.6, 27.5, 28.5, 31.0, 32.3, 32.9, 35.3, 37.6, 44.1, 45.9, 77.8, 78.9, 101.5, 102.6, 109.6, 110.1, 102.6, 109.6, 110.1, 113.3, 123.1, 124.0, 132.3, 133.2, 146.6, 161.0, 162.0, 165.0, 165.6, 178.1, and 178.5 ppm;
(viii) a thermogravimetric analysis (TGA) thermogram comprising a 20% w/w loss from about 125° C. to about 165° C.; and 70% w/w loss from about 165° C. to 200° C.; or
(ix) a differential scanning calorimetry (DSC) thermogram comprising an endothermic onset at about 149° C.

### Claim 22 (depends on 21)

The crystalline form of claim 21, wherein the single crystal belongs to the orthorhombic system, P212121 space group, and is characterized by the following single-crystal lattice parameters: a=11.4635(8)Å, b=18.0506(13)Å, c=19.2347(14)Å, α=90 degrees, β=90 degrees, and γ=90 degrees.

### Claim 23 (depends on 21)

The crystalline form of claim 21, wherein the single crystal x-ray diffraction (SCXRD) pattern is characterized by an Oak Ridge Thermal Ellipsoid Plot substantially as shown in FIG. 4.

### Claim 24

(canceled)

### Claim 25 (depends on 21)

The crystalline form of claim 21, characterized by a powder x-ray diffraction (PXRD) pattern substantially as shown in FIG. 5.

### Claim 26 (depends on 21)

The crystalline form of claim 21, characterized by a single crystal x-ray diffraction (SCXRD) pattern substantially as shown in FIGS. 44 and 45.

### Claim 27 (depends on 21)

The crystalline form of claim 21, characterized by the Fourier transform infrared spectroscopy spectrum substantially as shown in FIG. 8.

### Claim 28 (depends on 21)

The crystalline form of claim 21, characterized by the liquid state 1H nuclear magnetic resonance (NMR) spectrum substantially as shown in FIG. 2.

### Claim 29 (depends on 21)

The crystalline form of claim 21, characterized by the 1H-13C cross polarization (CP) magic-angle spinning (MAS) NMR spectrum substantially as shown in FIG. 7.

### Claim 30 (depends on 21)

The crystalline form of claim 21, further characterized by the solid state 1H NMR spectrum substantially as shown in FIG. 6.

### Claim 31 (depends on 21)

The crystalline form of claim 21, characterized by the liquid state 13C (1H decoupled) nuclear magnetic resonance (NMR) spectrum substantially as shown in FIG. 3.

### Claim 32 (depends on 21)

The crystalline form of claim 21, wherein the TGA thermogram comprises a degradation onset of about 125° C.

### Claim 33 (depends on 21)

The crystalline form of claim 21, characterized by the thermogravimetric analysis (TGA) thermogram substantially as shown in FIG. 9.

### Claim 34 (depends on 21)

The crystalline form of claim 21, wherein the crystalline form is further characterized by a differential scanning calorimetry thermogram comprising an endothermic event in the range of about 140° C. to 149° C.

### Claim 35 (depends on 21)

The crystalline form of claim 21, characterized by the differential scanning calorimetry (DSC) thermogram substantially as shown in FIG. 10.

### Claim 36

A method of preparing a single component crystalline form or a multicomponent crystalline form of tetrahydrocannabinolic acid (THCa) comprising:
suspending a plant extract comprising THCa in minimum amount (10-50% w/w) of a solvent at a temperature of about 25° C. to about 80° C.;
storing the suspension in at about −15° C. for about 6 to 48 hrs; and
repeating the process until obtaining a purified crystal.

### Claim 37

(canceled)

### Claim 38

A method of preparing a single component or multicomponent crystalline form of tetrahydrocannabinolic acid (THCa) comprising:
suspending a plant extract comprising THCa in a solvent at a temperature of about −15° C. to about 25° C. and
allowing the solvent to evaporate.

### Claim at position 23

-61. (canceled)

### Claim 62 (depends on 18)

The composition of claim 18, wherein the crystalline form further comprises a pharmaceutically acceptable carrier or an edible carrier.

### Claim 63

(canceled)
